Not provided
Not provided
Not provided
Not provided
Not provided
Business Considerations (difficulty with enrollment)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to pancreatic cancer. This study will include resected participants who are post pancreatic cancer surgery, and an additional cohort in non-resected participants.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Resected Participants Receiving Low Dose (12,000/6,000 units lipase) Pancrelipase | Experimental | Resected participants (surgery to remove pancreatic cancer) will first be given low dose pancrelipase. Low dose is defined as 12,000 USP units (lipase) with meals and 6000 U with snacks. At Weeks 1, 5, or 9, participants will be evaluated, and those who meet criteria for dose increase will be given high dose pancrelipase. High dose is defined as 72,000 U with meals and 36,000 U with snacks. All participants will receive placebo as needed to keep the number of pills the same in each group and for blinding. |
|
| Resected Participants Receiving High Dose (72,000/36,000 units lipase) Pancrelipase | Experimental | Resected participants (surgery to remove pancreatic cancer) will receive and continue on high dose pancrelipase throughout the study. High dose is defined as 72,000 USP units (lipase) with meals and 36,000 U with snacks. All participants will receive placebo as needed to keep the number of pills the same in each group and for blinding. |
|
| Non-Resected Participants Receiving High Dose (72,000/36,000 units lipase) Pancrelipase | Experimental | Non-resected participants (those who did not have surgery to remove pancreatic cancer) will receive high dose pancrelipase throughout the study in an open-label cohort. High dose is defined as 72,000 USP units (lipase) with meals and 36,000 U with snacks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pancrelipase | Drug | Pancrelipase is administered orally as capsules with a meal or snack |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Stool Fat From Baseline (Day 1) to Week 1 (Day 8) Among Participants With Resected Pancreatic Cancer | Stool samples were collected during the 48 hours prior to the Day 1 and Week 1 visits and analyzed for fat content. | Baseline (Day 1), Week 1 (Day 8) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Average Daily Stool Frequency From Baseline (Day 1) to Week 1 (Day 8) Among Participants With Resected Pancreatic Cancer | Participants recorded stool frequency using an electronic diary (eDiary). The average daily stool frequency was calculated from the last 3 days prior to the Baseline and Week 1 visits. | Baseline (Day 1), Week 1 (Day 8) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Alabama Oncology /ID# 207770 | Birmingham | Alabama | 35223-2437 | United States | ||
| Banner University of Arizona Medical Center Phoenix /ID# 208402 |
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link: https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Full Analysis Set: all randomized participants who received at least 1 dose of study drug. Neither the Resected Participants Receiving Low Dose Pancrelipase group nor the Non-Resected Participants Receiving High Dose Pancrelipase group enrolled any participants.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Resected Participants Receiving Low Dose (12,000/6,000 Units Lipase) Pancrelipase | Resected participants (surgery to remove pancreatic cancer) will first be given low dose pancrelipase. Low dose is defined as 12,000 USP units (lipase) with meals and 6000 U with snacks. At Weeks 1, 5, or 9, participants will be evaluated, and those who meet criteria for dose increase will be given high dose pancrelipase. High dose is defined as 72,000 U with meals and 36,000 U with snacks. All participants will receive placebo as needed to keep the number of pills the same in each group and for blinding. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Nov 22, 2019 | Mar 17, 2023 |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Drug | Placebo is administered orally as capsules with a meal or snack |
|
| Change in Stool Consistency From Baseline to Week 1 Among Participants With Resected Pancreatic Cancer | Participants recorded stool consistency using an electronic diary (eDiary). The change from Baseline to Week 1 is the proportion of days having watery stool consistency in the last 7 days prior to each of Baseline and Week 1 visits. Negative changes from Baseline indicate less frequent watery stools. | Baseline (Day 1), Week 1 (Day 8) |
| Change in the Total EPI Symptoms Score From Baseline to Week 1 Among Participants With Resected Pancreatic Cancer | The EPI Symptoms Questionnaire consists of 12 questions. The response scores range from 0 to 4 for each question (0 corresponding to None to 4 corresponding to Very Severe), with the total score ranging from 0 to 48. Positive changes indicate worsening from Baseline. | Baseline (Day 1), Week 1 (Day 8) |
| Phoenix |
| Arizona |
| 85006 |
| United States |
| UCSF Fresno /ID# 205757 | Fresno | California | 93701-2302 | United States |
| Stanford University School of Med /ID# 208821 | Stanford | California | 94305-2200 | United States |
| UCH-MHS Memorial Hospital Central /ID# 207093 | Colorado Springs | Colorado | 80909-4533 | United States |
| UCHealth Cancer Care and Hematology Clinic /ID# 207091 | Fort Collins | Colorado | 80528-3400 | United States |
| George Washington University Medical Faculty Associates /ID# 203363 | Washington D.C. | District of Columbia | 20037-3201 | United States |
| University of Florida - Archer /ID# 202679 | Gainesville | Florida | 32610 | United States |
| Columbus Regional Research Institute /ID# 211394 | Columbus | Georgia | 31904-8915 | United States |
| Northwest Community Hospital /ID# 202270 | Arlington Heights | Illinois | 60005-2355 | United States |
| NorthShore University HealthSystem /ID# 209026 | Evanston | Illinois | 60201 | United States |
| Ingalls Memorial Hosp /ID# 203962 | Harvey | Illinois | 60426 | United States |
| Advocate Christ Medical Center /ID# 203132 | Oak Lawn | Illinois | 60453-2600 | United States |
| University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 204407 | Ann Arbor | Michigan | 48109 | United States |
| Ascension Providence Hospital /ID# 203449 | Southfield | Michigan | 48075-4825 | United States |
| St. Louis University /ID# 205769 | St Louis | Missouri | 63104 | United States |
| Mercy Hospital South /ID# 221766 | St Louis | Missouri | 63128 | United States |
| Northwell Health Center for Liver Diseases /ID# 207321 | Manhasset | New York | 11030-3815 | United States |
| NYU Winthrop Hospital /ID# 207513 | Mineola | New York | 11501 | United States |
| New York University Langone Me /ID# 202290 | New York | New York | 10016 | United States |
| Columbia University Medical Center /ID# 204165 | New York | New York | 10032-3729 | United States |
| East Carolina University /ID# 206661 | Greenville | North Carolina | 27858 | United States |
| Gabrail Cancer Center Research /ID# 208030 | Canton | Ohio | 44718 | United States |
| Ohio State Cancer Center /ID# 203131 | Columbus | Ohio | 43210 | United States |
| Fox Chase Cancer Center /ID# 202288 | Philadelphia | Pennsylvania | 19111 | United States |
| Reading Hospital /ID# 206869 | Reading | Pennsylvania | 19611 | United States |
| Musc /Id# 210727 | Charleston | South Carolina | 29425 | United States |
| Tennessee Cancer Specialists /ID# 208235 | Knoxville | Tennessee | 37909 | United States |
| Vanderbilt University Medical Center /ID# 204231 | Nashville | Tennessee | 37232-0011 | United States |
| Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 206156 | Dallas | Texas | 75246-2003 | United States |
| UT MD Anderson Cancer Center /ID# 202271 | Houston | Texas | 77030 | United States |
| Wisconsin Center for Advanced Research, a division of GI Associates, LLC /ID# 205746 | Milwaukee | Wisconsin | 53215 | United States |
| Medical College of Wisconsin /ID# 205714 | Milwaukee | Wisconsin | 53226-3522 | United States |
| FG001 | Resected Participants Receiving High Dose (72,000/36,000 Units Lipase) Pancrelipase | Resected participants (surgery to remove pancreatic cancer) will receive and continue on high dose pancrelipase throughout the study. High dose is defined as 72,000 USP units (lipase) with meals and 36,000 U with snacks. All participants will receive placebo as needed to keep the number of pills the same in each group and for blinding. |
| FG002 | Non-Resected Participants Receiving High Dose (72,000/36,000 Units Lipase) Pancrelipase | Non-resected participants (those who did not have surgery to remove pancreatic cancer) will receive high dose pancrelipase throughout the study in an open-label cohort. High dose is defined as 72,000 USP units (lipase) with meals and 36,000 U with snacks. |
| COMPLETED |
|
| NOT COMPLETED |
|
Full Analysis Set: all randomized participants who received at least 1 dose of study drug
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Resected Participants Receiving Low Dose (12,000/6,000 Units Lipase) Pancrelipase | Resected participants (surgery to remove pancreatic cancer) will first be given low dose pancrelipase. Low dose is defined as 12,000 USP units (lipase) with meals and 6000 U with snacks. At Weeks 1, 5, or 9, participants will be evaluated, and those who meet criteria for dose increase will be given high dose pancrelipase. High dose is defined as 72,000 U with meals and 36,000 U with snacks. All participants will receive placebo as needed to keep the number of pills the same in each group and for blinding. |
| BG001 | Resected Participants Receiving High Dose (72,000/36,000 Units Lipase) Pancrelipase | Resected participants (surgery to remove pancreatic cancer) will receive and continue on high dose pancrelipase throughout the study. High dose is defined as 72,000 USP units (lipase) with meals and 36,000 U with snacks. All participants will receive placebo as needed to keep the number of pills the same in each group and for blinding. |
| BG002 | Non-Resected Participants Receiving High Dose (72,000/36,000 Units Lipase) Pancrelipase | Non-resected participants (those who did not have surgery to remove pancreatic cancer) will receive high dose pancrelipase throughout the study in an open-label cohort. High dose is defined as 72,000 USP units (lipase) with meals and 36,000 U with snacks. |
| BG003 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Count of Participants | Participants | No |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants | No |
| |||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants | No |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Stool Fat From Baseline (Day 1) to Week 1 (Day 8) Among Participants With Resected Pancreatic Cancer | Stool samples were collected during the 48 hours prior to the Day 1 and Week 1 visits and analyzed for fat content. | Participants who received at least one dose of study drug and who had evaluable stool fat at both Baseline and Week 1 visits | Posted | Mean | Standard Deviation | g/24 hours | Baseline (Day 1), Week 1 (Day 8) |
|
|
| ||||||||||||||||||||||||||||
| Secondary | Change in Average Daily Stool Frequency From Baseline (Day 1) to Week 1 (Day 8) Among Participants With Resected Pancreatic Cancer | Participants recorded stool frequency using an electronic diary (eDiary). The average daily stool frequency was calculated from the last 3 days prior to the Baseline and Week 1 visits. | Participants who received at least one dose of study drug | Posted | Mean | Standard Deviation | number of stools/day | Baseline (Day 1), Week 1 (Day 8) |
| ||||||||||||||||||||||||||||||
| Secondary | Change in Stool Consistency From Baseline to Week 1 Among Participants With Resected Pancreatic Cancer | Participants recorded stool consistency using an electronic diary (eDiary). The change from Baseline to Week 1 is the proportion of days having watery stool consistency in the last 7 days prior to each of Baseline and Week 1 visits. Negative changes from Baseline indicate less frequent watery stools. | Participants who received at least one dose of study drug | Posted | Mean | Standard Deviation | proportion of days w/ watery consistency | Baseline (Day 1), Week 1 (Day 8) |
| ||||||||||||||||||||||||||||||
| Secondary | Change in the Total EPI Symptoms Score From Baseline to Week 1 Among Participants With Resected Pancreatic Cancer | The EPI Symptoms Questionnaire consists of 12 questions. The response scores range from 0 to 4 for each question (0 corresponding to None to 4 corresponding to Very Severe), with the total score ranging from 0 to 48. Positive changes indicate worsening from Baseline. | Participants who received at least one dose of study drug | Posted | Mean | Standard Deviation | units on a scale | Baseline (Day 1), Week 1 (Day 8) |
|
All-cause mortality is reported from enrollment to end of study; time on follow up was 161 days. TEAEs and SAEs were collected from first dose of study drug until 30 days after last dose of study drug; time on study drug was 92 days.
Neither the "Resected Participants Receiving Low Dose (12,000/6,000 units lipase) Pancrelipase" group nor the "Non-Resected Participants Receiving High Dose (72,000/36,000 units lipase) Pancrelipase" group enrolled any participants.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Resected Participants Receiving Low Dose (12,000/6,000 Units Lipase) Pancrelipase | Resected participants (surgery to remove pancreatic cancer) will first be given low dose pancrelipase. Low dose is defined as 12,000 USP units (lipase) with meals and 6000 U with snacks. At Weeks 1, 5, or 9, participants will be evaluated, and those who meet criteria for dose increase will be given high dose pancrelipase. High dose is defined as 72,000 U with meals and 36,000 U with snacks. All participants will receive placebo as needed to keep the number of pills the same in each group and for blinding. | 0 | 0 | 0 | 0 | 0 | 0 |
| EG001 | Resected Participants Receiving High Dose (72,000/36,000 Units Lipase) Pancrelipase | Resected participants (surgery to remove pancreatic cancer) will receive and continue on high dose pancrelipase throughout the study. High dose is defined as 72,000 USP units (lipase) with meals and 36,000 U with snacks. All participants will receive placebo as needed to keep the number of pills the same in each group and for blinding. | 0 | 1 | 0 | 1 | 1 | 1 |
| EG002 | Non-Resected Participants Receiving High Dose (72,000/36,000 Units Lipase) Pancrelipase | Non-resected participants (those who did not have surgery to remove pancreatic cancer) will receive high dose pancrelipase throughout the study in an open-label cohort. High dose is defined as 72,000 USP units (lipase) with meals and 36,000 U with snacks. | 0 | 0 | 0 | 0 | 0 | 0 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| WHITE BLOOD CELLS DECREASED | Investigations | MedDRA 24.1 | Systematic Assessment |
| |
| PERIPHERAL SENSORY NEUROPATHY | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
| |
| FATIGUE | General disorders | MedDRA 24.1 | Systematic Assessment |
| |
| POSTURAL DIZZINESS | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
| |
| HYPERGLYCEMIA | Metabolism and nutrition disorders | MedDRA 24.1 | Systematic Assessment |
|
This study was terminated due to low enrollment rates. The decision to terminate the study was not based on any safety or efficacy data.
AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Global Medical Services | AbbVie | 800-633-9110 | abbvieclinicaltrials@abbvie.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Dec 13, 2020 | Mar 17, 2023 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D010188 | Exocrine Pancreatic Insufficiency |
| D010190 | Pancreatic Neoplasms |
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D020799 | Pancrelipase |
| ID | Term |
|---|---|
| D008049 | Lipase |
| D002265 | Carboxylic Ester Hydrolases |
| D004950 | Esterases |
| D006867 | Hydrolases |
| D004798 | Enzymes |
| D045762 | Enzymes and Coenzymes |
| D010184 | Pancreatic Extracts |
| D014020 | Tissue Extracts |
| D045424 | Complex Mixtures |
Not provided
Not provided
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
|
|
|
|
|
|